补充维生素D对支气管哮喘急性发作期患儿肺功能的影响  

Effect of Vitamin D Supplementation on Pulmonary Function in Children with Acute Exacerbation of Bronchial Asthma

作　　者：王辉[1] 杨波[1] WANG Hui;YANG Bo(Department of Pediatrics,People's Hospital of Mianzhu City,Mianzhu,Sichuan 618200,China)

机构地区：[1]绵竹市人民医院儿科,四川绵竹618200

出　　处：《临床误诊误治》2025年第8期68-72,共5页Clinical Misdiagnosis & Mistherapy

基　　金：四川省卫生健康委员会科研课题(19PJ221)。

摘　　要：目的探讨补充维生素D(VD)治疗对支气管哮喘急性发作期患儿肺功能的影响。方法选取2021年1月至2022年6月儿科门诊收治的80例支气管哮喘急性发作期患儿,采用随机数字表法分为观察组和对照组各40例。对照组在常规治疗基础上给予布地奈德气雾剂雾化吸入治疗,观察组在对照组基础上给予维生素D滴剂治疗,2组均治疗8周。比较2组临床症状、体征消失时间,治疗前后嗜酸粒细胞(EOS)、总免疫球蛋白E(TIgE)、血清25-羟维生素D 3[25-(OH)D 3]水平,治疗前后第1秒用力呼气容积(FEV1)、FEV1占用力肺活量比值(FEV1/FVC)、呼气峰值流速(PEF)、呼气高峰流量(PEFR),治疗前后儿童哮喘控制测试(C-ACT)评分、儿童生命质量量表(PedsQL)哮喘模块评分,以及治疗期间不良反应。结果观察组气喘、咳嗽、呼吸困难、肺哮鸣音消失时间均短于对照组(P<0.01)。治疗后,2组EOS、TIgE均低于治疗前(P<0.05),但组间比较无差异(P>0.05);治疗后,观察组25-(OH)D 3水平高于治疗前,且高于对照组(P<0.05,P<0.01)。治疗后,2组FEV1、FEV1/FVC、PEF、PEFR水平均高于治疗前,且观察组高于对照组(P<0.05,P<0.01)。治疗后,2组C-ACT评分、PedsQL哮喘模块评分均高于治疗前(P<0.05),但组间比较无差异(P>0.05)。治疗期间观察组不良反应发生率为20.00%(8/40),对照组为17.50%(7/40),比较差异无统计学意义(P>0.05)。结论补充VD治疗可明显缩短支气管哮喘急性发作期患儿临床症状体征持续时间,提高肺功能,且安全性较好。Objective To investigate the effect of vitamin D(VD)supplementation on pulmonary function in children with acute exacerbation of bronchial asthma.Methods Eighty children with acute exacerbation of bronchial asthma admitted to the pediatric clinic from January 2021 to June 2022 were divided into the observation group and the control group according to random number table method,with 40 patients in each group.The control group was given Budesonide aerosol inhalation on the basis of routine treatment,and the observation group was given vitamin D drops on the basis of the control group.Both groups were treated for 8 weeks.The disappearance time of clinical symptoms and signs,the levels of eosinophils(EOS),total immunoglobulin E(TIgE)and serum 25-hydroxyvitamin D 3[25-(OH)D 3]before and after treatment were compared between the two groups.Before and after treatment,forced expiratory volume in one second(FEV1),FEV1/forced vital capacity(FEV1/FVC),peak expiratory flow(PEF),peak expiratory flow rate(PEFR),Childhood Asthma Control Test(C-ACT)score and Pediatric Quality of Life Inventory(PedsQL)Asthma Module score,as well as adverse reactions during treatment,were compared between the two groups.Results The disappearance time of asthma,cough,dyspnea and lung rales in the observation group were shorter than those in the control group(P<0.01).After treatment,EOS and TIgE in the two groups were lower than those before treatment(P<0.05),but there was no difference between the two groups(P>0.05).After treatment,the level of 25-(OH)D 3 in the observation group was higher than that before treatment and that in the control group(P<0.05,P<0.01).After treatment,the levels of FEV1,FEV1/FVC,PEF and PEFR in the two groups were higher than those before treatment,which were higher in the observation group than in the control group(P<0.05,P<0.01).After treatment,the C-ACT score and PedsQL Asthma Module score of the two groups were higher than those before treatment(P<0.05),but there was no difference between the two groups(P>0.05).During

关 键 词：支气管哮喘 急性发作 儿童 维生素D 嗜酸粒细胞 第1秒用力呼气容积 儿童哮喘控制测试 药物毒性 

分 类 号：R725.6[医药卫生—儿科]